Clinical Trial Update: Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of axitinib for recurrent or metastatic adenoid cystic carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma

Drugs mentioned

• Kisplyx (axitinib) (axitinib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Recurrent ACC, metastaticACC, Unreaectable ACC | Phase 2 | Status: COMPLETED